Tirzepatide (Mounjaro) Shows Kidney Protective Effects in New Clinical Data

How Does Tirzepatide Protect the Kidneys?

The SURPASS clinical trial program (SURPASS 1–5 for type 2 diabetes) and the SURMOUNT program (for obesity) enrolled thousands of participants across multiple Phase 3 studies with follow-up ranging from 40 to 72 weeks. Preliminary post-hoc analyses of these trials have suggested that tirzepatide may slow the rate of eGFR decline and reduce albuminuria compared to placebo, though dedicated kidney outcome data are still being gathered. These findings echo the landmark FLOW trial, which demonstrated that the GLP-1 receptor agonist semaglutide reduced the risk of major kidney events by 24% in patients with type 2 diabetes and chronic kidney disease (published in the New England Journal of Medicine in 2024).

Urinary albumin-to-creatinine ratio (UACR), a marker of kidney damage, has also shown improvements in tirzepatide-treated patients across multiple trial analyses. Researchers note that the renoprotective effect may be partially independent of weight loss and HbA1c reduction, suggesting direct pharmacological effects. Preclinical studies have shown that GIP and GLP-1 receptors are expressed in kidney tubular cells and podocytes, where agonism may reduce inflammation, fibrosis, and oxidative stress. Whether tirzepatide's dual receptor mechanism confers additional kidney protection compared to GLP-1-only agonists remains an active area of investigation.

What Does This Mean for Patients with Kidney Disease?

Chronic kidney disease affects approximately 850 million people worldwide and is among the fastest-growing causes of death among non-communicable diseases. Current therapies that slow CKD progression include SGLT2 inhibitors (empagliflozin, dapagliflozin) — proven effective in the DAPA-CKD and EMPA-KIDNEY trials — the non-steroidal mineralocorticoid receptor antagonist finerenone (demonstrated in the FIDELIO-DKD and FIGARO-DKD trials), and ACE inhibitors/ARBs. The addition of GIP/GLP-1 receptor agonists could provide a complementary mechanism of renoprotection.

Eli Lilly is expected to pursue dedicated kidney outcomes studies for tirzepatide, following the model of Novo Nordisk's successful FLOW trial with semaglutide. In the interim, nephrologists note that many of their patients with diabetic kidney disease are already receiving tirzepatide for glucose and weight management, and the emerging data from post-hoc analyses provide reassurance of kidney safety and possible benefit. Major diabetes guidelines are beginning to acknowledge the growing renal evidence for incretin-based therapies, with the American Diabetes Association's Standards of Care increasingly recognizing GLP-1 receptor agonists as part of kidney risk management strategies.